Brokerages Set Illumina, Inc. (NASDAQ:ILMN) Price Target at $125.11

Shares of Illumina, Inc. (NASDAQ:ILMN - Get Free Report) have been given an average recommendation of "Hold" by the twenty analysts that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $125.11.

Several analysts have weighed in on the stock. Scotiabank downgraded shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price target for the company. in a research note on Friday. Evercore ISI raised their target price on shares of Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Canaccord Genuity Group raised their price target on shares of Illumina from $87.00 to $99.00 and gave the company a "hold" rating in a research report on Wednesday, June 11th. Royal Bank Of Canada reduced their price target on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research report on Tuesday, April 8th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating on the stock in a report on Friday, May 9th.

Illumina Stock Performance

Shares of Illumina stock traded down $0.72 during mid-day trading on Monday, hitting $98.53. 2,090,669 shares of the stock were exchanged, compared to its average volume of 2,408,865. Illumina has a 12 month low of $68.70 and a 12 month high of $156.66. The company has a 50-day simple moving average of $87.18 and a 200 day simple moving average of $95.94. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.48 and a current ratio of 1.86. The company has a market capitalization of $15.60 billion, a P/E ratio of -16.23, a P/E/G ratio of 1.95 and a beta of 1.36.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.01. Illumina had a negative net margin of 22.25% and a positive return on equity of 25.54%. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same quarter last year, the business posted $0.98 EPS. Illumina's quarterly revenue was down 1.4% compared to the same quarter last year. Sell-side analysts anticipate that Illumina will post 4.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Ankur Dhingra acquired 6,100 shares of Illumina stock in a transaction on Monday, May 12th. The shares were purchased at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the purchase, the chief financial officer directly owned 24,906 shares of the company's stock, valued at $2,022,616.26. The trade was a 32.44% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.17% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Freedom Investment Management Inc. grew its stake in shares of Illumina by 3.7% in the 4th quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company's stock worth $382,000 after purchasing an additional 101 shares during the last quarter. Moors & Cabot Inc. boosted its holdings in shares of Illumina by 2.5% during the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company's stock worth $465,000 after purchasing an additional 145 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Illumina by 16.4% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,108 shares of the life sciences company's stock worth $148,000 after purchasing an additional 156 shares during the period. Tokio Marine Asset Management Co. Ltd. lifted its stake in Illumina by 3.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company's stock valued at $445,000 after acquiring an additional 164 shares during the last quarter. Finally, Signaturefd LLC lifted its stake in Illumina by 10.4% in the fourth quarter. Signaturefd LLC now owns 1,880 shares of the life sciences company's stock valued at $251,000 after acquiring an additional 177 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.